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Abstract
Background: PPARc plays a key role in adipocyte biology, and Rosiglitazone (Rosi), a thiazolidinedione (TZD)/PPARc agonist,
is a potent insulin-sensitizing agent. Recent evidences demonstrate that adipose tissue inflammation links obesity with
insulin resistance and that the insulin-sensitizing effects of TZDs result, in part, from their anti-inflammatory properties.
However the underlying mechanisms are unclear.
Methodology and Principal Findings: In this study, we establish a link between free fatty acids (FFAs) and PPARc in the
context of obesity-associated inflammation. We show that treatment of adipocytes with FFAs, in particular Arachidonic Acid
(ARA), downregulates PPARc protein and mRNA levels. Furthermore, we demonstrate that the downregulation of PPARc by
ARA requires the activation the of Endoplamsic Reticulum (ER) stress by the TLR4 pathway. Knockdown of adipocyte PPARc
resulted in upregulation of MCP1 gene expression and secretion, leading to enhanced macrophage chemotaxis. Rosi
inhibited these effects. In a high fat feeding mouse model, we show that Rosi treatment decreases recruitment of
proinflammatory macrophages to epididymal fat. This correlates with decreased chemokine and decreased chemokine
receptor expression in adipocytes and macrophages, respectively.
Conclusions and Significance: In summary, we describe a novel link between FAs, the TLR4/ER stress pathway and PPARc,
and adipocyte-driven recruitment of macrophages. We thus both describe an additional potential mechanism for the anti-
inflammatory and insulin-sensitizing actions of TZDs and an additional detrimental property associated with the activation
of the TLR4 pathway by FA.
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Introduction
Free Fatty Acids (FFAs) are important adipocyte-derived
signaling molecules whose plasma levels are elevated in obese
and insulin resistant individuals and animal models. FFAs can
induce insulin resistance and inflammation in adipocytes,
macrophages and skeletal muscle [1,2,3,4,5,6]. In 3T3-L1
adipocytes, FFAs decrease adipocyte insulin sensitivity by
activating JNK signaling pathways, Endoplasmic Reticulum (ER)
stress and increasing secretion of the inflammatory cytokine TNFa
[7,8,9]. The pro-inflammatory and insulin desensitizing actions of
FFAs are mediated by stimulation of Toll-Like Receptor (TLR) 4
in adipocytes and TLR2 and TLR4 in macrophages [4,5,9,10].
Furthermore, FFAs induce the expression of and secretion of
numerous chemokines from adipocytes [11,12]. As these chemo-
kines (e.g. MCP1) potently recruit macrophages, FFAs may
indirectly induce insulin resistance, in vivo, by stimulating the
recruitment of pro-inflammatory leukocytes [13,14].
PPARc is a member of the nuclear hormone receptor
superfamily involved in numerous developmental and metabolic
processes in adipocytes, macrophages, liver, pancreatic beta-cells
as well as skeletal muscle [14,15,16,17,18,19]. Two isoforms of
PPARc have been described so far in mice, with PPARc2
expression being restricted to the adipocytes in white adipose tissue
[20]. Much of the insight into PPARc biology has been gained
from in vitro, in vivo and pharmacologic studies using natural and
synthetic PPARc ligands such as 15d-PGJ2 and insulin-
sensitizing thiazolidinediones (TZDs) like Rosiglitazone (Rosi)
[20,21,22,23,24]. In peritoneal macrophages, 15d-PGJ2 inhibits
gene expression of IP-10 and MCP-1, and treatment with TZDs
suppresses the expression and secretion of inflammatory cytokines
in monocytes and macrophages [25,26,27,28]. In 3T3L1 mature
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multiple glucose/fatty acid metabolism genes as well as adipokines
(e.g. adiponectin) [29,30]. PPARc-depleted adipocytes also
displayed enhanced inflammatory responses to TNF-alpha
stimulation, suggesting that PPARc also plays a role in regulating
inflammatory pathways in 3T3-L1 cells [29,30]. In vivo, mice
lacking PPARc in adipose tissue exhibited marked defects in
adipocyte morphology, reduced plasma adiponectin levels and
elevated plasma FFAs [16]. They were also more susceptible to
high fat diet-induced insulin resistance in adipose tissue and liver
[16,31,32]. When PPARc expression in macrophages was ablated
in mice, this resulted in systemic insulin resistance with attenuated
insulin sensitizing effects of TZDs [15]. Recently a novel PPARc
ligand was identified, which possessed weak transactivation but
maintained transrepression activity and retained antidiabetic
properties [27]. Together these studies suggest that the insulin-
sensitizing properties of PPARc are at least partially due to its anti-
inflammatory activity.
In the current studies, our aim was to identify whether there is
an interplay between FFAs and PPARc in the context of obesity-
associated inflammation. First, we show that FAs stimulate the
secretion of various chemokines from adipocytes into conditioned
medium (CM) and that Rosi treatment blocks this effect. Using
functional macrophage migration assays, we then demonstrate
that the chemotactic properties of CM were correlated to the
stimulatory and inhibitory effects of FAs and Rosi, respectively.
Furthermore, we present evidence that FAs, Arachidonic Acid
(ARA) in particular, decrease PPARc expression in a TLR4-
dependent manner, and that this effect is due to alteration in the
transcription of PPARc. We next investigated the mechanisms
involved in this downregulation and establish that ER stress
inducers also downregulate PPARc expression, whereas, ER stress
inhibitors prevented the ability of ARA to decrease the expression
of PPARc. Finally, when PPARc was depleted from adipocytes,
the chemotactic activity of CM was enhanced, indicating that
chemokine expression is tightly controlled in adipocytes by
mechanisms involving negative interactions between PPARc and
the FFAs, TLR4/ER stress pathway.
Results
PPARc signaling decreases secretion of chemoattractants
from adipocytes
We have previously shown that FFAs elevate chemokine
secretion from adipocytes [12]. To determine whether PPARc
activation inhibited this effect, 3T3-L1 adipocytes were treated
with FFAs (500 mM final concentrations of arachidonic, lauric,
linoleic, myristic and oleic acids, 100 mM final each), in the
absence or presence of Rosi (1 mM), followed by measurement of
Raw264.7 macrophage chemotaxis in response to adipocyte
conditioned media (CM). FFA treatment increased macrophage
migration, and this was prevented by Rosi pretreatment (Fig. 1A).
SiRNA-induced PPARc depletion (80% Fig. 1D) enhanced the
chemotactic properties of adipocyte CM (Fig. 1B) and also
increased MCP1 expression (Fig. 1C).
FFA treatment decreases adipocyte PPARc expression
To better characterize the molecular connections between FA-
induced chemotaxis and PPARc differentiated 3T3-L1 adipocytes
were treated with FFAs for 1–6 hours (Fig. 2A) and analyzed for
PPARc protein content by immunoblotting. FFA treatment led to
decreased PPARc protein levels in a time- and concentration-
dependent manner, with 70% depletion at 6 hours of incubation.
When individual FAs were tested (Fig. 2B), arachidonic (ARA),
lauric (LAU), linoleic (LIN), myristic (MYR) and oleic (OL) acids
decreased PPARc protein by ,40, 18, 20, 0, and 19%,
respectively. The down-regulation of PPARc by FFAs was also
observed in primary macrophages (Fig 2C). The effect of LPS
(5 ng/ml) is shown for comparison. As illustrated in Figure 2D,
transfection of the mPPARc2 promoter/luciferase construct
increased luciferase activity by ,4 fold (vehicle-treated cells with
pGL2 vs pNNf), as expected and previously reported [33]. When
adipocytes were treated with FFA or OL, luciferase activity was
decreased by ,33 and 40% respectively, whereas PAL treatment
had no effect. This indicated that the FA mixture and OL decrease
PPARc protein levels by decreasing PPARc promoter activity and
gene transcription. We also found that treatment with ARA, LAU,
LIN but not MYR can decrease PPARc promoter activity in 3T3-
L1 adipocytes (data not shown).
Arachidonic Acid prevents PPARc transrepressional
activity on chemokines secretion by adipocytes
As ARA had the greatest effect to down-regulate PPARc
expression (Figure 2B), we assessed the results of ARA treatment
on adipocyte chemoattractant secretion. In Figure 3A, we show
that 100 mM almost matched the stimulatory effect of 500 mMo f
the FFA cocktail on MCP1 secretion. Rosi pre-treatment
abolished the response to all the pro-inflammatory stimuli tested,
i.e. TNFa, FFAs and ARA. Furthermore, secretion of MCP1 by
adipocytes paralleled the chemotactic response observed in Fig. 1A.
We observed that ARA decreased PPARc RNA expression by
60% (Figure 3B), an effect that is similar to that known for its
agonist, Rosi [34,35]. We next measured the effect of ARA on
either the transrepressional or transactivational activity of PPARc.
As shown, in figure 3 C, ARA treatment did not hamper PPARc-
mediated transrepressional activity on MCP1 or KC expression.
In addition, whereas ARA repressed the expression of two known
PPARc target genes, adiponectin (AdipoQ) and aquaporin 7
(AQP7), Rosi still exhibited PPARc-mediated transactivational
activity even in presence of ARA (Figure 3D).
The downregulation of MCP1 expression by
Rosiglitazone does not require de novo protein synthesis
We tested whether the downregulation of chemokine expression
by Rosi involved direct PPARc transrepressional activity or
required synthesis of a PPARc-induced repressor protein. We thus
treated adipocytes with TNFa in the presence or absence of the
protein synthesis inhibitor, cycloheximide (CHX).
As seen in Figure 4, MCP1 expression was downregulated by
Rosi even in the presence of CHX, indicating that Rosi acted in a
direct manner (Fig. 4A). In the presence of CHX, MCP1 was not
detected in adipocyte CM, demonstrating the efficacy of CHX in
these experiments (Fig. 4B).
The downregulation of PPARc expression by FFAs
requires TLR4 dependent activation of the ER stress
To determine the mechanisms involved in FFA-induced
downregulation of PPARc expression we pretreated adipocytes
with TLR4 (5A, 5B) or TNFa (not shown) neutralizing antibodies
prior to treatment with FFAs (500 mM, 3 hours). Whereas
neutralizing TNFa did not alter the ability of FFAs to decrease
PPARc expression, neutralizing TLR4 prevented this effect at the
protein (5A) and gene expression level (5B). As ER stress is a
known side effects associated with FAs exposure and TLR
activation, we next tested whether ER stress inducers would
mimic the detrimental effects of FAs treatments [8,36]. As shown
in figure 5 C, we indeed observed that similar to ARA, the ER
Transrepressional Activity of PPARc in Adipocytes
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1 mg/ml), strongly decreased the expression of PPARc (280% and
290% respectively). In addition, the ER stress response gene
CHOP-10 was upregulated with the downregulation of PPARc.
This was also correlated with the increased expression of the
chemokine KC. We consequently tested whether ER stress
inhibitors could interfere with the ability of ARA to downregulate
the expression of PPARc in mature 3T3L1 adipocytes. We found
that treatment with the two chemical chaperones, 4-phenyl
butyrate (PBA, 10 mM)) and tauroursodeoxycholic acid (TUDCA,
500 mg/ml), strongly prevented the downregulation of ARA-
induced PPARc expression. Six hours of treatment with ARA
(100 mM) decreased PPARc protein level to 24% compared to
untreated cells. PBA and TUDCA treatment maintained PPARc
expression to a relative level of 74% and 64% respectively
(Figure 5D). This effect was also seen at the transcriptional level
(PPARc RNA, fig. 5E). In addition, we looked at other mediators
of TLR4 biological actions. Consequently, we knocked down
IRF3, TAK1 and JNK and observed that these manipulations did
not interefere with the ability of FAs to decrease PPARc
expression (not shown) [8,37,38]. Lastly, overexpression of a
super-repressor of NFkB (DN-IkB) also had no effect (not shown).
Figure 1. PPARc signaling decreases secretion of chemoattractants from adipocytes. A) Mature 3T3L1 adipocytes were exposed 24 hours
to 500 mM FFA mixture (arachidonic, lauric, linoleic, myristic and oleic acids, 100 mM final each) in presence or absence of Rosi (1 mM). After washes,
24 hours adipocytes conditioned media were prepared, in absence of treatment and used for chemotaxis assay on Raw264.7 macrophages. B) PPARc
siRNA or controls (Ctrl) were injected in mature 3T3L1 adipocytes. 24 hours after electroporation, adipocytes were exposed to FFA mixture or vehicle,
for 16 hours. After washes, 24 hours adipocytes conditioned media were prepared, in absence of treatment and used for chemotaxis assay on
Raw264.7 macrophages. C) QPCR was used to quantify PPARc and MCP1 from the adipocytes treated as above. D) Western-blots were performed in
order to quantify efficient PPARc knockdown, HSP90 protein is shown as internal control. * P,0.05; # P,0.05 for Rosi vs Vehicle in absence of FFA in
1A; and for PPARc siRNA vs Luciferase siRNA in absence of FFA.
doi:10.1371/journal.pone.0034976.g001
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adiposity with decreased Adipose Tissue Macrophage
(ATM) content
To determine whether our in vitro findings on chemokine
secretion and macrophage chemotaxis translate to the in vivo
situation, we quantified macrophage markers in epididymal fat of
mice fed either normal chow or high fat diet (HFD) for 16 weeks in
the presence or absence of Rosi. Both CD68 and F4/80 (Fig. 6A)
expression were increased by HFD, which indicated an increased
presence of ATMs. Expression of these markers was strikingly
diminished upon Rosi treatment. Feeding with HFD was also
associated with an increase in epididymal fat weight, which was
Figure 2. Free Fatty Acid treatment decreases adipocyte PPARc expression. Differentiated 3T3-L1 adipocytes were treated with 300 mM and
500 mM of a mixture of saturated and unsaturated FFAs for 1–6 hours (A), or with 500 mM of individual FFAs for 3 hours (B) (ARA, arachidonic acid;
LAU, lauric acid; LIN, linoleic, acid; MYR, myristic acid; OL, oleic acid). Cell lysates were then analyzed for PPARc protein content by SDS-PAGE
fractionation and immunoblotting using a monoclonal antibody that detects PPARc1 and PPARc2 isoforms. Densitometric analysis of PPARc protein
collected from multiple experiments is presented in the right panels (A and B) *P,0.05. C) IPMacs were treated for the indicated times with LPS (5 ng/
ml) or FFAs mixture (500 mM) and PPARc expression was quantified by QPCR. D) 3T3-L1 adipocytes were electroporated with plasmids encompassing
parts of the mouse (m)PPARc2 promoter (PNNf) or no promoter (pGL2) fused to the firefly luciferase gene, along with the beta-galactosidase plasmid.
Cells were treated with the FA mixture or with OL and PAL, the two major FAs found in plasma and then lyzed. Luciferase and beta-galactosidase (for
normalization) activities were assayed. # P,0.05 for pNNf vs pGL2; * P,0.05 for pNNf of veh-control vs FA treatment.
doi:10.1371/journal.pone.0034976.g002
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was quantified with ELISA from 24 hours 3T3L1 conditioned media (A). Conditioned media were either prepared from adipocytes not stimulated
(Veh), treated with TNFa (10 ng/ml), with 500 mM of FFAs mixture (containing 100 mM Arachidonic Acid) or with 100 mM of Arachidonic Acid (ARA)
alone. Cotreatment with Rosi (1 mM) was also perfomed (white bars). Media used for preparation of conditioned media is shown for reference (2).
QPCR analysis of PPARc (B) MCP1 and KC (C) and adiponectin (AdipoQ) and aquaporin 7 (AQP7) (D) expression in 3T3L1 adipocytes exposed to
100 mM of Arachidonic Acid (ARA), Rosi (1 mM) or both compounds; ** p,0.01 vs Untreated, # p,0.05 vs Rosi. Letters above the bars show statistical
groups (p,0.05).
doi:10.1371/journal.pone.0034976.g003
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Thus, the correlation between adiposity and ATMs was
dissociated with Rosi treatment (Fig. 6C).
We and others have shown that the proinflammatory
macrophages which accumulate in adipose tissue express high
levels of CD11c [39,40]. Thus, we prepared Stromal Vascular
Cells (SVCs), the macrophage containing cellular fraction, from
adipose tissue for FACS analysis. The FACS results show that
HFD increased the number of F4/80+, CD11b+, CD11c+ ATMs,
which was normalized by Rosi treatment (fig. 6D). Decreased
ATMs recruitment was confirmed with adipose tissue immuno-
histochemistry staining of F4/80+ cells (Fig. 6E). Interestingly,
decreased ATMs content was only observed after three weeks
treatment with rosiglitazone and no difference were observed after
one week treatment with Rosi. However, in vivo tracking
experiments with labeled macrophages demonstrate that ATMs
are long lived cells as injected macrophages are still detectable 28
days after injection [41]. Consequently one could porpose that
even though rosiglitazone may quickly lead to a decreased
expression and secretion of chemokines, this may not immediately
translate in a decrease of ATMs.
Rosiglitazone decreases chemokine expression in
adipocytes and chemokine receptor expression in SVCs
To better understand the mechanism of macrophage recruit-
ment to adipose tissue and the effects of Rosi on this process, we
measured mRNA expression of known chemokines in adipocyte
fractions prepared from epididymal fat pads (Fig. 7A). HFD led to
increased expression of all the measured adipocyte-derived
chemokines; i.e., fractalkine (CX3CL1), MCP-1 (CCL2), MIP1a
(CCL3), and RANTES (CCL5). In contrast, the expression of
Eotaxin-1 (CCL11), an eosinophil specific chemokine [42], did not
change. We also prepared SVCs for analysis. As seen in Fig. 7B,
HFD led to increased expression of all the corresponding
chemokine receptors. Rosi treatment had broad effects to decrease
the HFD-induced increase in chemokine and chemokine receptor
gene expression.
In figure 7C, we observed an interesting parallel between the
expression of chemokines reported in 7A and PPARc in
adipocytes fraction. Indeed, in high fat diet conditions, the
downregulation of PPARc was associated with the increased
expression of the chemokines, whereas treatment with Rosi
restored PPARc expression, while decreasing the expression of
chemokines.
Adipose tissue TNFa expression was also increased by HFD and
repressed by Rosi treatment Fig. 7D). Since TNFa can stimulate
chemokine secretion [12,43], this observation raises the possibility
that Rosi affects chemokine expression by down regulating TNFa.
CD68 and GLUT4 are markers for macrophages and
adipocytes, respectively, and Fig. 7E indicates minimal cross
contamination between these fractions.
Discussion
In this study, we show that in vitro, FFA treatment of fat cells,
particularly ARA, leads to an increase in chemokine expression
and secretion from these cells and enhances macrophage
migration in chemotaxis assays. These effects are most likely due
to the actions of FFAs to activate proinflammatory pathways
within adipocytes, which, would in turn stimulate chemokine gene
expression and secretion [5,9,12,44]. We further present evidence
linking the actions of FFAs to decreased PPARc activity. We
report that FFA treatment led to downregulation of PPARc
expression both in adipocytes and macrophages and that siRNA-
mediated knockdown of PPARc resulted in increased chemokine
secretion from adipocytes as well as increased functional
chemotaxic activity of CM harvested from PPARc -depleted
adipocytes. These results are likely of physiological importance as
they suggest that FFAs exert their stimulatory effects, at least in
part, by causing decreased PPARc expression both in adipocytes
and macrophages. Rosi treatment reverses all of these FFA effects
on chemokines/chemokine receptors, which further reinforces the
important role of PPARc signaling in this mechanism. As PPARc
signaling normally serves to keep chemokine and chemokine
receptor expression low, our results provide a mechanistic
explanation as to the pathway whereby FFAs induce chemo-
kine/chemokine receptor expression.
These findings translated to the in vivo situation. Our animal
data show that HFD led to increased expression of chemokines in
mouse tissue adipocytes along with a corresponding increase in
chemokine receptors in stromal vascular cell fractions from
epididymal fat pads. Recent work indicates the existence of a
feed forward pathway between FAs released from adipocytes and
cytokine secretion by macrophages, in which FFAs can activate
proinflammatory pathways in macrophages and cytokines released
from macrophages can stimulate lipolysis in adipocytes [43]. The
FAs also lead to proinflammatory effects in adipocytes causing
increased chemokine secretion. In addition, FFAs also led to
decreased PPARc expression in macrophages, contributing to
Figure 4. The downregulation of MCP1 expression by Rosi does not require de novo protein synthesis. 3T3L1 were treated for 1 Hr with
10 mM cycloheximide (CHX), followed by 1 Hr with Rosi (1 mM) and 5 hours with TNFa (10 ng/ml). MCP1 expression was then quantified with QPCR
(A) whereas MCP1 secretion was quantified with ELISA in the corresponding conditioned media (B). ** P,0.01; N.D., Not Detected.
doi:10.1371/journal.pone.0034976.g004
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further support that PPARc plays an important role in integrating
communication between the adipocyte and macrophage cell types
in the overall chemotactic response of immune cells to chemokines
released by adipocytes.
Even though, it is well established that chemokine secretion
govern ATMs recruitment in vivo, the exact nature of the initial
stimuli that drives this program is a subject of intense debate.
Several stimuli upstream of chemokines expression and secretion
have been proposed so far, including adipocyte interactions with
the extracellular matrix, hypoxia and ER stress [45] [13]. Our
findings support the idea that ER stress is an essential component
in the recruitment of macrophages in response to an obesogenic
environment. In agreement with our observations, Jiao et al
described that FFA induce ER stress, which further cause insulin
resistance in adipocytes [7]. In our manuscript, we bring forward
evidences that FFAs may cause ER stress, which decreases PPARc
expression in adipocytes. The exact mechanisms involved in this
regulation are still unclear. However, it is known that CHOP-10
displays transrepressional activity on several genes, which further
worsens the consequences of ER stress [8,46]. In particular, it was
demonstrated that CHOP-10 decreases the expression of PPARc
in a mechanism involving the sequestration of C/EBPb and
limiting its binding to the PPARc promoter [47]. The mechanism
proposed in this publication perfectly fits with our observations as
PPARc expression is regulated by C/EBPb binding in adipocytes
[48]. Further illustrating the contribution of the TLR4 pathway to
this regulation, it is acknowledged that TLR4 activation by LPS
Figure 5. The downregulation of PPARc expression by FFAs requires TLR4dependent activation of the ER stress. 3T3L1 adipocytes
were pretreated with neutralizing antibodies to TLR4 (A, B), or control IgG prior to FA treatment (500 mM, 3 hr). Adipocyte PPARc protein content was
assessed as above, by immunoblotting analysis (A) and mRNA by real time qPCR (B). C) Mature 3T3L1 were treated with tunicamycin (TUN, 1 mg/ml)
and thapsigargin (TG, 50 nM) for the indicated times prior to extract RNA and quantify PPARc, CHOP-10 and KC with qPCR. D) Mature 3T3L1
adipocytes were pretreated 3 hours with 14-phenyl butyrate (PBA, 10 mM) and tauroursodeoxycholic acid (TUDCA, 500 mg/ml) prior to be exposed
to ARA (100 mM) for 6 hours. Proteins were then extracted and PPARc was quantified by western-blot. E) Mature 3T3L1 adipocytes were pretreated
3 hours with 14-phenyl butyrate (PBA, 10 mM) before exposure to 100 mM ARA. PPARc expression was quantified with qPCR. ** P,0.01.
doi:10.1371/journal.pone.0034976.g005
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markers, CD68 and F4/80, in epidydimal WAT of mice fed 16 weeks with a normal chow diet (NCD), a high fat diet (HFD) in absence or presence of
Rosi. Epididymal fat weights of mice described above (B) and association between CD68 expression and eWAT (C) * P,0.05; ** P,0.01. D) Facs
analysis of F4/80, CD11b and CD11c were performed on cells from stromal vascular fractions of mice fed with normal chow, high fat diet (16 weeks)
or high fat diet for 13 weeks followed by three weeks treatment with Rosi. Plots data represent the relative expression of CD11b and CD11c in F4/80
gated cells. E) Immunostaining of F4/80 on eWAT section of mice fed a high fat diet alone (16 weeks) or in presence of Rosi for the last three weeks.
doi:10.1371/journal.pone.0034976.g006
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macrophages chemokines in adipocytes fraction (A) and corresponding receptors (B) in stromal vascular fraction were quantified with QPCR. Eotaxin-
1 and corresponding receptor, CCR3 are shown in white, MIP1a and RANTES corresponding receptors CCR1 and CCR5 are shown in light grey,
Fractalkine and corresponding receptor CX3CR1 are shown in dark grey, MCP1 and corresponding receptor, CCR2, are shown in black. C) QPCR
analysis of PPARc in adipocytes and SV fractions. D) TNFa expression in stromal vascular fraction was determined by qPCR. D) CD68 and Glut4
expression were quantified from SVF and adipocytes fractions by qPCR. ** P,0.01. A, B above the bars show statistical groups (p,0.05).
doi:10.1371/journal.pone.0034976.g007
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future work should be conducted to fully establish that the ER
stress is necessary to the TLR4 pathway in order to downregulate
the expression of PPARc in response to FFA.
Our studies further show that Rosi blocked the effects of HFD
on chemokine/chemokine receptor expression. These molecular
events reflected the state of ATMs accumulation: HFD led to
increased ATM content which was completely reversed by three
weeks of Rosi treatment. Interestingly, we and others observed
that PPAR activators downregulate the expression of PPARc in
3T3L1 adipocytes [34,35,50], and herein report that Rosi, a
potent PPARc agonist, also decreases PPARc expression. It has
been surmised that in adipocytes the downregulation of PPARc
induced upon binding of an agonist most likely describes an auto-
regulation process [34]. As illustrated through the expression of
PPARc target genes, the presence of Rosi overwhelms the
downregulation induced by both its exogenous agonist and FAs.
This could explain why Rosi is observed to be still fully active in
preventing macrophages infiltration in vivo and in vitro despite such
a reduction in receptor availability.
In macrophages, the anti-inflammatory properties of TZDs
largely rely on PPARc’s ability to decrease the expression of pro-
inflammatory cytokines and chemokines, i.e. PPARc transrepres-
sional activity. In adipocytes, the adipogenic/transactivational
activity of PPARc is well established; however, very little is known
about PPARc’s anti-inflammatory/transrepressional properties in
adipocytes. Our manuscript establishes how elevated FAs, as
would be observed in the context of obesity, decrease PPARc
expression, which further prevents PPARc transrepressional
activity, further resulting in the upregulation of macrophage
chemoattractant secretion by adipocytes. This loop of interactions
between fatty acids and PPARc is of particular interest since a
recent publication demonstrates that beneficial properties of TZDs
may widely rely on PPARc transrepressional/anti-inflammatory
properties [27].
Arachidonic acid and its metabolites are known to activate
inflammatory responses in a variety of immune cells [51].
However, in adipocytes, the effects of ARA are poorly document-
ed. We found that ARA was uniquely potent in downregulating
PPARc expression and in stimulating the ability of adipocyte CM
to promote chemotaxis. Interestingly, a recent publication reports
that deletion of 12/15-lipoxygenase (an enzyme that produces
metabolites from ARA) in mice leads to protection from HFD-
induced ATM recruitment and inflammation [52]. Thus, the ARA
stimulation of chemokine expression in response to adipocytes
could involve elevated production of 12/15-lipoxygenase products
from ARA.
In summary, our studies show that FFAs decrease PPARc
protein and mRNA levels by decreasing PPARc gene transcrip-
tion. This results in increased MCP1 gene expression and
enhanced adipocyte-induced monocyte/macrophage chemotaxis.
Together our findings indicate that high FFA and low PPARc
levels could enhance the recruitment of inflammatory macro-
phages into adipose tissue, contributing to the development of
tissue inflammation and insulin resistance. Moreover, TZD
treatment may decrease inflammation and improve insulin
sensitivity, at least in part, by decreasing ATM recruitment
through transrepressional mechanisms directly within adipocytes.
Materials and Methods
Ethics Statement
Mouse procedures conformed to the Guide for Care and Use of
Laboratory Animals of the US National Institutes of Health, and
were approved by the Animal Subjects Committee of the
University of California, San Diego, CA, USA (UCSD protocol
# S99173).
Chemicals and Reagents
Cycloheximide, lipopolysaccharide (LPS), free fatty acids,
thapsigargin, arachidonic, lauric, linoleic, myristic and oleic acids
were from Sigma. Tunicamycin, 14-phenyl butyrate and taur-
oursodeoxycholic acid were from Calbiochem. Rosiglitazone was
from Alexis. Antibodies to PPARc and horseradish peroxidase
(HRP)-linked secondary antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). Dubbelco’s Modified Eagle
Medium (DMEM) and fetal bovine serum were purchased from
Invitrogen (Carlsbad, CA). TNFa was from Biosource. Low
endotoxin, fatty acids free-BSA was from MP Biochemicals
(Aurora, OH). PPARc promoter-luciferase reporter plasmid was
kindly gifted by Dr Reddy JK [33].
Cell culture
Mouse 3T3L1 cells were grown and maintained undifferenti-
ated in DMEM (25 mM glucose) supplemented with 10% Bovine
Calf Serum (Hyclone) and differentiated to 3T3L1 adipocytes as
previously described (14). Raw264.7 cells were maintained in 10%,
low endotoxin FBS (Hyclone) DMEM (25 mM glucose). Unless
indicated otherwise, adipocytes were used 10 days after differen-
tiation. Cells were serum-starved in DMEM supplemented with
FA-free bovine albumin and treated with an FFA cocktail
composed of lauric, myristic, linoleic, oleic and arachidonic acids
(1:1:1:1:1) or individual FAs (lauric, myristic, linoleic, oleic,
arachidonic and palmitic; Sigma-Aldrich) or ethanol/PBS vehicle
for indicated amounts of time at 37uC. All FA solutions were pre-
equilibrated with BSA at 37uC for 1.5 hour and a 5:1 (mol/mol)
FA:BSA ratio was used to simulate elevated FFAs levels [3].
3T3L1 and Raw 264.7 cells were obtained from ATCC (American
Type Culture Collection, Manassas, VA).
SiRNA electroporation
SiRNAs were obtained from IDT. Sequences for PPARc
duplexes were as described by Liao [29]. Adipocytes at day +6
from differentiation protocol were collected and electroporated
with siRNAs as previsouly described (GENE PULSER; Bio-Rad)
[29].
Neutralizing TLR4 signaling
Prior to the addition of FFAs, each well in a 12-well culture
plate was supplemented with Toll- Like Receptor 4 (TLR4) (e-
Bioscience, San Diego, CA) neutralizing antibody or control
Armenian IgG (10 mg/ml final concentration).
In vitro chemotaxis assay
Following incubation with FFAs or vehicle, 3T3-L1 adipocytes
were rinsed with warm DMEM to remove treatments. Cells were
subsequently incubated in DMEM containing 0.2% BSA for
24 hours. Conditioned medium (CM) was collected and kept
frozen in single-use aliquots. For the chemotaxis assay, 600 mlo f
adipocyte CM was aliquoted per well of 24-well tissue culture
plates, and 200.000 RAW264.7 macrophage cells resuspended in
DMEM containing 0.2% of endotoxin- and FFA-free BSA were
plated in the upper transwell chamber (8 mm, 24-transwell format;
Corning, Lowell, MA). After 3 hours of migration, Raw264.7 cells
were fixed in formaldehyde and stained with DAPI. Cells in the
upper chamber that had not migrated were removed. RAW264.7
cells found on the filter facing the lower chamber were counted as
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PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e34976cells having performed chemotaxis and quantified with the Simple
PCI imaging software (Compix Inc., Cranberry Township, PA)
[12].
Animal experiments
Male C57BL/6J mice (littermates) were obtained from Jackson
Laboratories and housed four per cage under pathogen free
conditions. 10 weeks old mice were fed a high fat diet (60% Kcal
fat, Research Diet) where Rosi was directly mixed by manufac-
turer. Normal chow diet consisted of 13,5% kcal fat (Lab Diet). In
figure 5A, 5B and 5C, mice were fed the different diets for 16
weeks. In figure 5D and 5E, mice were fed a normal chow or a
high fat diet for 16 weeks that included Rosi for the last three
weeks in the designated group.
Immunohistochemistry
Adipose (epididymal) tissue was fixed in paraformaldehyde
(10%) for 24 hours prior to paraffin imbedding. F4/80 (serotec)
staining was performed as described previously [40]. Brightfield
photographs were taken of 5 representative fields per slide in a
blinded fashion using a fluorescent microscope (106objective).
Epididymal and adipocytes isolation and FACS analysis of
macrophages
Detailed experimental procedures are described by Inouye
[53]. In brief, epididymal fat pads were harvested and minced in
FACS buffer. Tissues were treated with collagenase for 30 min at
37 C. After treatment, the suspension was filtered and centrifu-
gated. The adipocyte fraction consisted of the supernatant. The
SVF pellets were incubated with red blood cell lysis buffer and
directly used for RNA isolation or resuspended in FACS buffer.
The stromal vascular cells (SVC) were incubated with blocker
followed by primary and secondary antibodies with washes in
between. SVC were analyzed using FACSCalibur and FACSAria
flow cytometers.
RNA isolation and quantitative PCR
Total RNA was extracted from cells or tissue with Trizol
(Invitrogen) reagent. Total RNA was reverse-transcribed with
using ABI cDNA Synthesis Kit (Applied biosciences). Primer
sequences used in the PCR reactions were chosen based on the
sequences available in GenBank and were designed to generate a
PCR amplification product of 100–200 bp. Only primer pairs
yielding unique amplification products without primer dimer
formation were subsequently used. Primer sequences are available
upon request. PCR was performed as described [40]. The mRNA
expression of all genes reported is normalized to the cyclophilin A
gene expression.
Protein isolation and Western blots
Proteins from tissues or cell lysates were extracted with RIPA
buffer (Upstate) in presence of phosphatase- and protease-
inhibitors (Roche). 20 mg of proteins per lane were separated on
10% polyacrylamide, precasted SDS gel (biorad) followed by a
transfer on PVDF membrane (Immobilon, Millipore) and
immunoblotting was performed as described [29].
ELISA assays
MCP1 was directly quantified from media according to
manufacturers instructions (Biosource).
Statistical analysis
Data represent the means 6 S.D. and were evaluated by
Student’s two-tailed t-test or analysis of variance provided by
VassarStats: Web Site for Statistical Computation. A p value cut-
off of 0.05 was used to determine significance.
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